{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:58:32Z","timestamp":1793879912510,"version":"4.7.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Amgen and UCB"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2003<\/jats:title>\n                    <jats:p>Romosozumab, a humanized monoclonal antibody that binds and inhibits sclerostin, has the dual effect of increasing bone formation and decreasing bone resorption. As previously reported in the pivotal FRActure study in postmenopausal woMen with ostEoporosis (FRAME), women with a T-score of \u2264 \u20132.5 at the total hip or femoral neck received subcutaneous placebo or romosozumab once monthly for 12 months, followed by open-label subcutaneous denosumab every 6 months for an additional 12 months. Upon completion of the 24-month primary analysis period, eligible women entered the extension phase and received denosumab for an additional 12 months. Here, we report the final analysis results through 36 months, including efficacy assessments of new vertebral, clinical, and nonvertebral fracture; bone mineral density (BMD); and safety assessments. Of 7180 women enrolled, 5743 (80%) completed the 36-month study (2851 romosozumab-to-denosumab; 2892 placebo-to-denosumab). Through 36 months, fracture risk was reduced in subjects receiving romosozumab versus placebo for 12 months followed by 24 months of denosumab for both groups: new vertebral fracture (relative risk reduction [RRR], 66%; incidence, 1.0% versus 2.8%; p &amp;lt; 0.001), clinical fracture (RRR, 27%; incidence, 4.0% versus 5.5%; p\u2009=\u20090.004), and nonvertebral fracture (RRR, 21%; incidence, 3.9% versus 4.9%; p\u2009=\u20090.039). BMD continued to increase for the 2 years with denosumab treatment in both arms. The substantial difference in BMD achieved through 12 months of romosozumab treatment versus placebo was maintained through the follow-up period when both treatment arms received denosumab. Subject incidence of adverse events, including positively adjudicated serious cardiovascular adverse events, were overall balanced between groups. In conclusion, in postmenopausal women with osteoporosis, 12 months of romosozumab led to persistent fracture reduction benefit and ongoing BMD gains when followed by 24 months of denosumab. The sequence of romosozumab followed by denosumab may be a promising regimen for the treatment of osteoporosis. \u00a9 2018 American Society for Bone and Mineral Research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jbmr.3622","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T13:54:31Z","timestamp":1543845271000},"page":"419-428","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":203,"title":["One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study"],"prefix":"10.1093","volume":"34","author":[{"given":"E Michael","family":"Lewiecki","sequence":"first","affiliation":[{"name":"New Mexico Clinical Research & Osteoporosis CenterAlbuquerqueNMUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajani V","family":"Dinavahi","sequence":"additional","affiliation":[{"name":"Amgen Inc.Thousand OaksCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marise","family":"Lazaretti-Castro","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o PauloS\u00e3o PauloBrazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R","family":"Ebeling","sequence":"additional","affiliation":[{"name":"Monash UniversityMelbourneAustralia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D","family":"Adachi","sequence":"additional","affiliation":[{"name":"McMaster UniversityHamiltonONCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimitsu","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Miyauchi Medical CenterOsakaJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Gielen","sequence":"additional","affiliation":[{"name":"University Hospitals LeuvenLeuvenBelgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra E","family":"Milmont","sequence":"additional","affiliation":[{"name":"Amgen Inc.Thousand OaksCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Libanati","sequence":"additional","affiliation":[{"name":"UCB PharmaBrusselsBelgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Grauer","sequence":"additional","affiliation":[{"name":"Amgen Inc.Thousand OaksCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"issue":"3","key":"2024021014515602600_jbmr3622-bib-0001","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024021014515602600_jbmr3622-bib-0002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/gerona\/glt105","article-title":"Death, debility, and destitution following hip fracture","volume":"69","author":"Tajeu","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"2024021014515602600_jbmr3622-bib-0003","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ard.2008.092775","article-title":"Clinical subsequent fractures cluster in time after first fractures","volume":"68","author":"van Geel","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"2024021014515602600_jbmr3622-bib-0004","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"2024021014515602600_jbmr3622-bib-0005","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1359\/jbmr.090207","article-title":"Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001","volume":"24","author":"Ryg","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024021014515602600_jbmr3622-bib-0006","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00198-005-2026-x","article-title":"Risk of new clinical fractures within 2 years following a fracture","volume":"17","author":"van Helden","year":"2006","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024021014515602600_jbmr3622-bib-0007","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024021014515602600_jbmr3622-bib-0008","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO Trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024021014515602600_jbmr3622-bib-0009","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024021014515602600_jbmr3622-bib-0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00198-003-1514-0","article-title":"Fracture risk following an osteoporotic fracture","volume":"15","author":"Johnell","year":"2004","journal-title":"Osteoporos Int"},{"issue":"6","key":"2024021014515602600_jbmr3622-bib-0011","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00198-017-3976-5","article-title":"Imminent fracture risk","volume":"28","author":"Roux","year":"2017","journal-title":"Osteoporos Int"},{"issue":"7","key":"2024021014515602600_jbmr3622-bib-0012","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jbmr.3429","article-title":"High imminent vertebral fracture risk in subjects with COPD with a prevalent or incident vertebral fracture","volume":"33","author":"van Dort","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024021014515602600_jbmr3622-bib-0013","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/art.10787","article-title":"Hip fracture patients are not treated for osteoporosis: a call to action","volume":"47","author":"Harrington","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2024021014515602600_jbmr3622-bib-0014","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00198-003-1544-7","article-title":"Undertreatment with anti-osteoporotic drugs after hospitalization for fracture","volume":"15","author":"Panneman","year":"2004","journal-title":"Osteoporos Int"},{"issue":"12","key":"2024021014515602600_jbmr3622-bib-0015","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1007\/s00198-014-2827-x","article-title":"Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA","volume":"25","author":"Wilk","year":"2014","journal-title":"Osteoporos Int"},{"issue":"19","key":"2024021014515602600_jbmr3622-bib-0016","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"2024021014515602600_jbmr3622-bib-0017","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend Trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"2024021014515602600_jbmr3622-bib-0018","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"2024021014515602600_jbmr3622-bib-0019","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"9999","key":"2024021014515602600_jbmr3622-bib-0020","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"2024021014515602600_jbmr3622-bib-0021","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2024021014515602600_jbmr3622-bib-0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"16","key":"2024021014515602600_jbmr3622-bib-0023","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2024021014515602600_jbmr3622-bib-0024","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jbmr.3439","article-title":"A post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024021014515602600_jbmr3622-bib-0025","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024021014515602600_jbmr3622-bib-0026","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/jbmr.3036","article-title":"Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Ominsky","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2024021014515602600_jbmr3622-bib-0027","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","article-title":"Effects of sclerostin antibodies in animal models of osteoporosis","volume":"96","author":"Ominsky","year":"2017","journal-title":"Bone"},{"issue":"1","key":"2024021014515602600_jbmr3622-bib-0028","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00223-017-0258-3","article-title":"Romosozumab treatment converts trabecular rods into trabecular plates in male cynomolgus monkeys","volume":"101","author":"Matheny","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"2024021014515602600_jbmr3622-bib-0029","article-title":"Effects of romosozumab in postmenopausal women with osteoporosis after 2 and 12 months assessed by microCT on Iliac crest bone biopsies","author":"Roux","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024021014515602600_jbmr3622-bib-0030","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/jbmr.3176","article-title":"Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass","volume":"32","author":"Keaveny","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2024021014515602600_jbmr3622-bib-0031","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","article-title":"Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis","volume":"81","author":"Graeff","year":"2015","journal-title":"Bone"},{"issue":"7","key":"2024021014515602600_jbmr3622-bib-0032","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME Study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"15","key":"2024021014515602600_jbmr3622-bib-0033","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2024021014515602600_jbmr3622-bib-0034","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024021014515602600_jbmr3622-bib-0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"2","key":"2024021014515602600_jbmr3622-bib-0036","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024021014515602600_jbmr3622-bib-0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161435.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr Pract"},{"key":"2024021014515602600_jbmr3622-bib-0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"issue":"1","key":"2024021014515602600_jbmr3622-bib-0039","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","volume":"103","author":"Horne","year":"2018","journal-title":"Calcif Tissue Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.3622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.3622","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/34\/3\/419\/56654379\/jbmr3622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/34\/3\/419\/56654379\/jbmr3622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:03:06Z","timestamp":1710327786000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/34\/3\/419-428\/7605837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,12,3]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3622","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734573568.793584759","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,1]]},"published":{"date-parts":[[2018,12,3]]},"assertion":[{"value":"2018-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}